Comparative Pharmacology
Head-to-head clinical analysis: ILOTYCIN versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOTYCIN versus R P MYCIN.
ILOTYCIN vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking peptidyl transferase activity and preventing translocation of peptides.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
Erythromycin base (Ilotycin): 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day. For IV: 15-20 mg/kg/day continuous infusion or divided every 6 hours.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours in adults, prolonged to 4-6 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-15% biliary/fecal elimination.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic